NeOnc Technologies is preparing to go public via the less common path of a direct listing as it continues mid-stage testing of its intranasally administered brain cancer drug. Meanwhile, the mostly stagnant biotech IPO pipeline is showing new signs of life with two large stock market debuts expected this week.
The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer.
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
Chimerix is selling global rights to smallpox drug Tembexa, the biotech’s only FDA-approved product, as a way to fund clinical development of a therapy in pivotal testing for a rare type of brain cancer. The deal marks Chimerix’s nearly complete departure from the antiviral work that defined the company for most of its history.
Almost no new therapies have succeeded in extending patient survival in GBM in the last 20 years, and the field is littered with drugs that have failed despite promising early data. But researchers soldier on with new molecular targets and therapeutic modalities.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.
The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat and invariably fatal disease.
Tempe, Arizona-based GT Medical Technologies has developed the GammaTile, a surgically targeted brachytherapy technology for the treatment of recurrent brain tumors.
Simply put, working together is better than working alone. At MedCity CONVERGE, three panelists discussed an organization based on the idea of collaboration: the Philadelphia Coalition for a Cure, which is seeking to put an end to brain cancer.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.
At ASCO 2016, Cleveland Clinic researchers examined the impact of the number of brain metastases on overall survival for two common cancer types: Non-small cell lung cancer and gastroesophageal cancer.
Just this month, the company received orphan drug designation in both the European Union and America for treating glioblastoma.
Celldex's brain cancer vaccine improves survival rates and, importantly, improves quality of life, according to new topline results just released by the company.
Palo Alto startup Orbus Therapeutics just reeled in $32.5 million to bring eflornithine, an already-approved drug for hirsutism and sleeping sickness, into Phase 3 trials for brain cancer.